Hemostatic Effect of Various Colloid Solutions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00518544|
Recruitment Status : Unknown
Verified August 2007 by Samsung Medical Center.
Recruitment status was: Recruiting
First Posted : August 20, 2007
Last Update Posted : August 20, 2007
Background: Individuals with type O blood have reduced factor VIII and von Willebrand factor levels compared to the non-O counterpart. Infusion of hydroxyethyl starch (HES) impairs coagulation and, in O blood type, apparent coagulopathy can develop after HES infusion. A newly market-released balanced HES (670/0.75) has physiologic pH and balanced electrolytes including calcium, which are beneficial to coagulation. Studies comparing balanced HES (670/0.75) with saline-based HES (130/0.4), previously known the least coagulopathic are rare. Therefore, we try to reveal the difference of coagulation, pH/electrolyte balance, and bleeding amount between the non-O and O blood types after infusion of these two newest HES.
Methods: Each 20 of non-O and type O ASA 1 or 2 patients scheduled for spinal surgery involving 2 or 3 spinal levels were enrolled. 20 ml/kg of saline-based HES (130/0.4) or balanced HES (670/0.75) was administered during operation. Blood loss, coagulation and metabolic profiles were checked at pre-infusion (T0), 5 min after infusion (T1), 4 hrs after infusion (T2) and 24 hrs after infusion (T4).
|Condition or disease||Intervention/treatment|
|Laminectomy||Drug: administration of hydroxyehtyl starch|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Hemostatic Effect of Various Colloid Solutions According to Blood Types|
|Study Start Date :||July 2007|
Drug: administration of hydroxyehtyl starch
- Blood loss, coagulation and metabolic profiles [ Time Frame: pre-infusion, 5 min after infusion, 4 hrs after infusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518544
|Contact: Hyun Joo Ahn, MD., PhD.||email@example.com|
|Korea, Republic of|
|Samsung medical center||Recruiting|
|Seoul, Korea, Republic of, 135-710|
|Contact: Hyun Joo Ahn, MD.,PhD. 82-2-3410-0784 firstname.lastname@example.org|
|Principal Investigator:||Hyun Joo Ahn, MD., PhD.||Samsung Medical Center|